1498P - Efficacy and Safety of Trabectedin in an Elderly Patient Subgroup (≥65 years) with Advanced Leiomyosarcoma (LMS) or Liposarcoma (LPS) from the Expa...

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Soft Tissue Sarcomas
Geriatric Oncology
Cancer in Special Situations
Sarcoma
Presenter Robin Jones
Citation Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387
Authors R.L. Jones1, R. Maki2, S. Patel3, G. Wang4, C.R. Shin5, R. Knoblauch6, G.D.S. Demetri7
  • 1Sarcoma Unit, Royal Marsden Hospital/Institute of Cancer Research, SM2 5NG - London/GB
  • 2Medical Oncology And Hematology, Monter Cancer Center, Lake Success/US
  • 3Oncology, The University of Texas, MD Anderson Cancer Center, Houston/US
  • 4Biostats, Janssen Research & Development, LLC, Spring House/US
  • 5Med Group Oncology, Janssen Scientific Affairs, LLC, Horsham/US
  • 6Clinical Oncology, Janssen Research & Development, LLC, 8869 - Raritan/US
  • 7Center For Sarcoma And Bone Oncology, Dana-Farber Cancer Institute and Ludwig Center at Harvard, Boston/US

Abstract

Background

Elderly patients (pts) (≥65 yrs) with soft tissue sarcoma may have limited treatment options due to increased comorbidities and toxicities from available therapeutic agents. Previous retrospective analyses have suggested that trabectedin (T) has similar safety and efficacy outcomes irrespective of pt age.

Methods

In this multicenter, open-label study, pts received IV T (1.5 mg/m2) every 3 wks. We retrospectively analyzed the efficacy and safety of T in pts ≥65 yrs treated from 2005-2010 on this EAP.

Results

Mean age was 71 and 49 in the ≥65 (n = 350) and 12 mo) was 26 (7.4%) and 107 (7.4%) in the ≥65 and

Conclusions

The efficacy and safety profile of T in pts ≥65 was similar to that observed in pts

Clinical trial identification

NCT00210665

Legal entity responsible for the study

Janssen Research & Development, LLC

Funding

Janssen Research & Development, LLC

Disclosure

R.L. Jones: Consultant for: Adaptimmune, Blueprint, Eisai, Epizyme, Daichii, Deciphera, Janssen Scientific Affairs, LLC, Immunedesign, Lilly, Merck, Pharmamar. R. Maki: Consulting or advisory role: SARC, ASCO, AADX, ARCUS, Bayer, GSAI, GEM, Novartis, GSK, Immune Design, Janssen, Kyropharm, Lilly Tracon and Presage. Research funding & travel, accommodations, expenses: Tracon, Immune Design, Lilly and SARC. S. Patel: Consultant to: Janssen, Eisai, Novartis, CytRx, Epizyme, Bayer, Eli Lilly. Grants for clinical trial from: Janssen, Eisai, Morphotek. G. Wang, C.R. Shin, R. Knoblauch: Employment with Janssen and Johnson & Johnson stock ownership. G.D.S. Demetri: Consulting: Novartis, Janssen, PharmaMar, Daiichi-Sankyo, Adaptimmune, Eisai Patent licensed to Novartis from Dana-Farber with royalty paid to Dana-Farber Research support to Dana-Farber: Novartis, Janssen.